Growth hormone secretagogues include peptides with different jobs
Secretagogues are substances that get glands to release hormones. That’s the whole job of the word. For this pair, the interesting part is how each ingredient sends the message.
The gland hears more than one kind of signal
Growth hormone comes from the pituitary, a little gland tucked under the brain. Growth hormone-releasing hormone, often shortened to GHRH, is one of its signals. CJC-1295 works through that pathway. The FDA’s CJC-1295 assessment explains the related forms.
Ipamorelin works through the ghrelin receptor. A receptor is a receiving point for a chemical message. Ghrelin is involved in appetite as well as hormone release, so this is a different signal with some shared effects.
A hunger signal has more than one job

Ghrelin is made in the stomach. Ipamorelin acts at its receptor; that connection doesn’t make every effect the same.
The early ipamorelin experiments found a selective growth hormone response in animals. That means certain stress hormones didn’t rise as they did with some older peptides. It doesn’t mean the substance has only one action, or no side effects.
These ingredients ask the body to release its own growth hormone; they don’t supply growth hormone. The FDA assessments explain that someone with a complete lack of growth hormone production will not respond to these signals. Explaining that mechanism cannot tell you whether you have a deficiency.
Two signals don’t supply a finished answer
Different signals can work together. Bowers and colleagues studied a related pair in men and found a combined hormone response larger than simple addition. That’s synergy. The study offers a reason to investigate, but it didn’t test the CJC-1295 and ipamorelin blend.
The CJC form still matters. DAC is an attachment that helps it bind albumin, a blood protein, and last longer. The human CJC-1295 study used that longer-acting form. Dropping DAC changes which substance we’re talking about.
Route matters as well. Gobburu’s ipamorelin study in human volunteers gave it into a vein. That tells us about that experiment, rather than every way the ingredient might be given. It didn’t test the pair.
Prompting hormone release can also have unwanted effects. The wider safety review flags blood sugar and how well the body responds to insulin. Neither ingredient is FDA-approved, and none of these component studies establishes the combination’s long-term safety.
So when you see “growth hormone secretagogue,” read it as a description of an action. The next question is whether that action helps with the proposed use at an acceptable risk. The research page follows the evidence for that question.
Two routes to hormone release explain the idea behind the pair. They don’t yet tell us what the actual combination does for people.